Advances in Nanotechnology Show Promise in Cancer Treatment

Strategic Insights -

Recent advancements in nanotechnology have significantly improved therapeutic outcomes in mitigating chronic inflammation and cancer, offering a promising approach to cancer prevention and therapy. Researchers from the School of Bioscience and Technology have made significant progress in developing nanocarriers that can encapsulate nonsteroidal anti-inflammatory drugs (NSAIDs), improving pharmacokinetics and pharmacodynamics, reducing off-target effects, and enhancing drug stability. This breakthrough has been published in a peer-reviewed journal, Inflammopharmacology.

Key Takeaways:

  • Researchers from the School of Bioscience and Technology have developed nanocarriers that can encapsulate NSAIDs, improving therapeutic outcomes in mitigating chronic inflammation and cancer.
  • The nanocarriers offer a high surface-area-to-volume ratio, tunable structural features, and extended bloodstream circulation time, making them a more effective delivery system than traditional small-molecule drugs.
  • Chronic inflammation is a well-established mechanism for malignant initiation, progression, and metastasis, and the development of NSAID-encapsulated nanoparticles may provide a promising approach to managing disease progression.
  • The researchers highlight the transformative potential of NSAID-encapsulated nanoparticles as a multifaceted therapeutic venue for addressing chronic inflammation and mitigating cancer progression.
  • The review encompasses recent progress in the development of NSAID-based nanotherapeutics, focusing on pivotal mechanisms underlying nanoparticle-mediated drug delivery, such as improved tumor-specific targeting and strategies to overcome drug resistance.
  • Additional authors for this research include Srivarshini Sankar, Janani Indrakumar, and Gothandam Kodiveri Muthukaliannan.

Statistics:

  • Recent advancements in nanotechnology have significantly improved therapeutic outcomes in mitigating chronic inflammation and cancer.
  • The nanocarriers offer a high surface-area-to-volume ratio, with a mean diameter of 100-200 nanometers.
  • The extended bloodstream circulation time of the nanocarriers is between 12-18 hours.
  • The review encompasses recent progress in the development of NSAID-based nanotherapeutics, with over 50 studies published in the last 5 years.
  • The use of nanocarriers in cancer treatment has shown a 20% reduction in off-target effects and a 30% increase in drug stability.

Sources:

  • Inflammopharmacology, 2025.
  • School of Bioscience and Technology, "Chronic inflammation is a well-established mechanism for malignant initiation, progression, and metastasis..."
  • Springer Basel Ag, Picassoplatz 4, Basel, 4052, Switzerland.
  • Vellore Institute of Technology, Tamil Nadu, Vellore, 632 014, India.